<DOC>
	<DOCNO>NCT01705327</DOCNO>
	<brief_summary>This observational , multi-center study assess clinical feature biologic biomarkers Parkinson 's disease ( PD ) patient compare healthy control ( HC ) . The primary objective study discover clinical biologic marker PD use clinical trial disease-modifying therapy .</brief_summary>
	<brief_title>Fox Investigation New Discovery Biomarkers</brief_title>
	<detailed_description>BioFIND two-year observational clinical study design discover verify biomarkers Parkinson 's disease ( PD ) . BioFIND collect clinical data biospecimens , include blood cerebrospinal fluid ( CSF ) , population 120 well-defined , moderately advanced PD subject 120 healthy control . BioFIND follow standardize data acquisition protocols ensure test assessment conduct multiple site pool . Data sample acquire study participant enable development comprehensive Parkinson 's database biorepository , available scientific community conduct research novel PD biomarkers .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Inclusion Criteria ( PD Subjects ) : Subjects must bradykinesia rigidity . Current history well document rest tremor . Unilateral onset persistent asymmetry . A well establish response dopaminergic agent include presence levodopa induce dyskinesia least 3 year accord treat physician 's judgment . Subject progressive PD 5 18 year duration onset symptom . Male female age onset PD 50 70 history . Current age would range 55 93 base # 5 # 6 requirement . Ability provide write informed consent accordance Good Clinical Practice ( GCP ) , International Conference Harmonization ( ICH ) , local regulation . Willing able comply schedule visit , require study procedure laboratory test . Exclusion Criteria ( PD Subjects ) : Family history PD first degree relative . Ashkenazi Jewish subject ( defined 4 grandparent Ashkenazi Jewish ) exclude high likelihood genetic form PD ( LRRK2 ) GBA ) , unless already exclude genetic testing . Has others serious neurological disorder ( clinically significant stroke , brain tumor , hydrocephalus , epilepsy , neurodegenerative disorder , encephalitis , repeat head trauma ) . Has early severe autonomic involvement . Symptomatic orthostatic , hypotension urinary incontinence within one year onset disease symptom . Current treatment anticoagulant ( e.g. , Coumadin , heparin ) might preclude safe completion lumbar puncture . Condition preclude safe performance routine lumbar puncture , prohibitive lumbar spinal disease , bleed diathesis , clinically significant coagulopathy thrombocytopenia . Any medical psychiatric condition lab abnormality , opinion investigator might preclude participation . Use investigational drug device within 60 day prior baseline ( dietary supplement take outside clinical trial exclusionary , e.g. , coenzyme Q10 ) . Has low body predominant symptom . Has supranuclear gaze palsy , CG sign , corticospinal track sign . Inclusion Criteria ( HC Subjects ) : Male female age 55 93 year visit 1 . Ability provide write informed consent accordance Good Clinical Practice ( GCP ) , International Conference Harmonization ( ICH ) , local regulation . Willing able comply schedule visit , require study procedure laboratory test . Exclusion Criteria ( HC Subjects ) : Family history PD first degree relative . Ashkenazi Jewish subject ( defined 4 grandparent Ashkenazi Jewish ) exclude high likelihood genetic form PD ( LRRK2 ) GBA ) , unless already exclude genetic testing . Has serious neurological disorder ( clinically significant stroke , brain tumor , hydrocephalus , epilepsy , neurodegenerative disorder , encephalitis , repeat head trauma ) . Has history cancer , autoimmune disorder , liver disease , hematological disorder within past 5 year . Has early severe autonomic involvement : symptomatic orthostatic hypotension urinary incontinence within one year onset disease symptom . Current treatment anticoagulant ( e.g. , Coumadin , heparin ) might preclude safe completion lumbar puncture . Condition preclude safe performance routine lumbar puncture , prohibitive lumbar spinal disease , bleed diathesis , clinically significant coagulopathy thrombocytopenia . Any medical psychiatric condition lab abnormality , opinion investigator might preclude participation . Use investigational drug device within 60 day prior baseline ( dietary supplement take outside clinical trial exclusionary , e.g. , coenzyme Q10 ) . MoCA score &lt; 26 .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>93 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Parkinson 's</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Neurodegenerative disorder</keyword>
</DOC>